How long should Ado-trastuzumab emtansine be used?

According to the prescribing information for Ado-trastuzumab emtansine, the dosage is based on the patient's weight, and the infusion is repeated every 3 weeks. Patients with metastatic breast cancer (MBC) should receive trastuzumab until disease progression or uncontrollable toxicity; patients with early-stage breast cancer (EBC) should receive trastuzumab for a total of 14 cycles unless disease relapse or uncontrollable toxicity occurs. During and after the infusion, patients should be observed for any infusion-related reactions, such as flushing, chills, and fever. For patients who experience allergic reactions or side effects, the treating physician may need to reduce the dose or discontinue trastuzumab treatment.